OKYO Pharma (NASDAQ:OKYO - Get Free Report)'s stock had its "sell (d-)" rating reiterated by investment analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.
A number of other research analysts have also recently commented on the company. Zacks Research upgraded OKYO Pharma to a "hold" rating in a report on Tuesday, September 16th. HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of OKYO Pharma in a report on Tuesday, September 23rd. Finally, Wall Street Zen upgraded OKYO Pharma to a "hold" rating in a report on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $7.00.
Read Our Latest Report on OKYO Pharma
OKYO Pharma Stock Performance
Shares of OKYO Pharma stock opened at $2.39 on Friday. The stock's 50 day simple moving average is $2.19 and its 200-day simple moving average is $2.16. OKYO Pharma has a 1-year low of $0.90 and a 1-year high of $3.35.
Institutional Trading of OKYO Pharma
A hedge fund recently bought a new stake in OKYO Pharma stock. Wealth Enhancement Advisory Services LLC bought a new stake in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,000 shares of the company's stock, valued at approximately $28,000. 2.97% of the stock is owned by hedge funds and other institutional investors.
About OKYO Pharma
(
Get Free Report)
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OKYO Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.
While OKYO Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
